Showing 4461-4470 of 6411 results for "".
- NB-UVB Phototherapy Effective for Psoriasis in Skin of Colorhttps://practicaldermatology.com/news/nb-uvb-phototherapy-effective-for-psoriasis-in-skin-of-color/2483263/A new systematic review and meta-analysis confirms that narrowband ultraviolet B (NB-UVB) phototherapy is effective for psoriasis in patients with skin of color, underscoring its role as a valuable treatment option despite the widespread adoption of biologics and systemic agents.
- Skin Microbiome and Aging: Connected for the Long Haul?https://practicaldermatology.com/news/skin-microbiome-and-aging-connected-for-the-long-haul/2483286/The skin microbiome is not just a passive reflection of age, but in fact may be a key player in how skin ages and its ability to resist decline. During her presentation on the intersection of microbiomes and skin aging at the 2025 Science of Skin Summit in Austin, TX, Julia Oh, PhD, a prof
- Early Childhood Stress Tied to Psoriasis Riskhttps://practicaldermatology.com/news/early-childhood-stress-tied-to-psoriasis-risk/2483262/A prospective cohort study from Sweden suggests that early childhood stress, particularly disruptions in family structure, may increase the risk of developing psoriasis later in life. The research, published in the Journal of Investigative Dermatology
- Analysis: GLP-1 Receptor Agonists Linked with Reduced Surgical/Hospitalization Burden in HShttps://practicaldermatology.com/news/analysis-glp-1-receptor-agonists-reduced-surgical-and-hospitalization-burden-in-hs/2483172/New real-world data suggest that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are linked with reduced surgical interventions and hospitalizations in patients with hidradenitis suppurativa (HS). Researchers using real
- Bimekizumab Achieves Dual Clearance of Nail and Skin Psoriasishttps://practicaldermatology.com/news/bimekizumab-achieves-dual-clearance-of-nail-and-skin-psoriasis/2483170/In pooled analyses of phase III and IIIb trials, bimekizumab was associated with significantly higher rates of complete clearance of both skin and nail psoriasis compared to adalimumab, ustekinumab, and secukinumab in patients with moderate-to-severe plaque psorias
- JAK Inhibitors Linked to Lower Adjunctive Therapy Use Than Dupilumab in ADhttps://practicaldermatology.com/news/jak-inhibitors-linked-to-lower-adjunctive-therapy-use-than-dupilumab-in-ad/2483122/Patients with atopic dermatitis (AD) treated with oral Janus kinase (JAK) inhibitors used fewer adjunctive therapies over the long term compared to those receiving dupilumab, according to a retrospective study published ahead of print in
- Deucravacitinib Shows Sustained Efficacy in Plaque Psoriasis Through 3 Years: Studyhttps://practicaldermatology.com/news/deucravacitinib-shows-sustained-efficacy-in-plaque-psoriasis-through-3-years-study/2483055/Deucravacitinib, a first-in-class oral selective TYK2 inhibitor, has demonstrated durable efficacy and a favorable safety profile in patients with moderate-to-severe plaque psoriasis, according to a recent review of phase III and long-term data.
- Review: Psoriasis May Increase Infection Risk After Hip Arthroplastyhttps://practicaldermatology.com/news/review-psoriasis-may-increase-infection-risk-after-hip-arthroplasty/2483053/Patients with psoriasis undergoing total hip arthroplasty (THA) may face a higher risk of postoperative infection, with evidence regarding total knee arthroplasty (TKA) outcomes remaining inconclusive, according to a new systematic review,
- Study: AGE-Inhibitor Cream Improves Skin Tone and Firmness Post-Treatmenthttps://practicaldermatology.com/news/study-age-inhibitor-cream-improves-skin-tone-and-firmness-post-treatment/2483017/An AGE-inhibiting moisturizer significantly improved post-procedure facial appearance following glycolic acid peels or radiofrequency microneedling, particularly among women with skin of color. Researchers for the randomized,
- Bimekizumab Outperforms IL-17 Inhibitors in Real-World Psoriasis Studyhttps://practicaldermatology.com/news/bimekizumab-shows-edge-over-il-17-inhibitors-in-polish-real-world-psoriasis-study/2482980/Bimekizumab demonstrated a faster and more robust response than secukinumab and ixekizumab in a real-world cohort of Polish patients with moderate-to-severe plaque psoriasis. Researchers conducted a retrospective analysis fro